Lessons learned from the development of oral calcitonin: The first tablet formulation of a protein in phase III clinical trials

Journal of Clinical Pharmacology

Volumn 51, Issue 4, 2011, Pages 460-471

  Karsdal, M A ^a   Henriksen, K ^a   Bay Jensen, A C ^a   Molloy, B ^b   Arnold, M ^b   John, M R ^b   Byrjalsen, I ^a   Azria, M ^b   Riis, B J ^a   Qvist, P ^a   Christiansen, C ^a,c  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b NOVARTIS PHARMA AG   (Switzerland)

^c CCBR/SYNARC   (Denmark)

Author keywords

Bone; Calcitonin; Cartilage; Clinical trial; Oral formulation

Indexed keywords

8 (N 2 HYDROXY 5 CHLOROBENZOYL)AMINO CAPRYLIC ACID; BIOLOGICAL MARKER; CALCITONIN; DRUG CARRIER; ENZYME INHIBITOR; UNCLASSIFIED DRUG; WATER;

CLINICAL TRIAL; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG UPTAKE; EVENING DOSAGE; HUMAN; MORNING DOSAGE; OSTEOLYSIS; OSTEOPOROSIS; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TABLET FORMULATION;

ADMINISTRATION, ORAL; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CALCITONIN; FOOD-DRUG INTERACTIONS; GASTRIC EMPTYING; HUMANS; OSTEOPOROSIS; PEPTIDE FRAGMENTS; TABLETS;

EID: 79951615188     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010372625     Document Type: Review

References (80)

1. Van den MG. Colon drug delivery. Expert Opin Drug Deliv. 2006;3:111-125.
2. Shareef MA, Khar RK, Ahuja A, Ahmad FJ, Raghava S. Colonic drug delivery: an updated review. AAPS PharmSci. 2003;5:E17.
3. Wiktor-Jedrzejczak W, Urbanowska E, Aukerman SL, et al. Correction by CSF-1 of defects in the osteopetrotic op/op mouse suggests local, developmental, and humoral requirements for this growth factor. Exp Hematol. 1991;19:1049-1054.
4. Yamamoto M, Tachikawa S, Maeno H. Effects of porcine calcitonin on behavioral and electrophysiological responses elicited by electrical stimulation of the tooth pulp in rabbits. Pharmacology. 1982;24:337-345. (Pubitemid 12081044)
5. Lee YH, Sinko PJ. Oral delivery of salmon calcitonin. Adv Drug Deliv Rev. 2000;42:225-238. (Pubitemid 30645779)
6. Torres-Lugo M, Peppas NA. Transmucosal delivery systems for calcitonin: a review. Biomaterials. 2000;21:1191-1196. (Pubitemid 30195716)
7. Buclin T, Cosma RM, Burckhardt P, Azria M, Attinger M. Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers. J Bone Miner Res. 2002;17:1478-1485. (Pubitemid 34803831)
8. Sakuma S, Suzuki N, Sudo R, Hiwatari K, Kishida A, Akashi M. Optimized chemical structure of nanoparticles as carriers for oral delivery of salmon calcitonin. Int J Pharm. 2002;239:185-195. (Pubitemid 34615808)
9. Guggi D, Kast CE, Bernkop-Schnurch A. In vivo evaluation of an oral salmon calcitonin-delivery system based on a thiolated chitosan carrier matrix. Pharm Res. 2003;20:1989-1994.
10. Wang J, Chow D, Heiati H, Shen WC. Reversible lipidization for the oral delivery of salmon calcitonin. J Control Release. 2003;88:369-380. (Pubitemid 36331879)
11. Tanko LB, Bagger YZ, Alexandersen P, et al. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover. J Bone Miner Res. 2004;19:1531-1538. (Pubitemid 41094356)
12. Bernkop-Schnurch A, Hoffer MH, Kafedjiiski K. Thiomers for oral delivery of hydrophilic macromolecular drugs. Expert Opin Drug Deliv. 2004;1:87-98. (Pubitemid 40297958)
13. Lamprecht A, Yamamoto H, Takeuchi H, Kawashima Y. pH-sensitive microsphere delivery increases oral bioavailability of calcitonin. J Control Release. 2004;98:1-9. (Pubitemid 38881602)
14. Bagger YZ, Tanko LB, Alexandersen P, et al. Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone. 2005;37:425-430. (Pubitemid 41160502)
15. Manicourt DH, Azria M, Mindeholm L, Thonar EJ, Devogelaer JP. Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. Arthritis Rheum. 2006;54:3205-3211. (Pubitemid 44622091)
16. Sondergaard BC, Oestergaard S, Christiansen C, Tankó LB, Karsdal MA. The effect of oral calcitonin on cartilage turnover and surface erosion in an ovariectomized rat model. Arthritis Rheum. 2007;56:2674-2678. (Pubitemid 47237285)
17. Mustata G, Dinh SM. Approaches to oral drug delivery for challenging molecules. Crit Rev Ther Drug Carrier Syst. 2006;23:111-135. (Pubitemid 44403815)
18. Mustata G, Dinh SM. Drug delivery global summit - evaluating emerging technologies. Expert Opin Drug Deliv. 2005;2:185-187. (Pubitemid 40123892)
19. Streubel A, Siepmann J, Bodmeier R. Gastroretentive drug delivery systems. Expert Opin Drug Deliv. 2006;3:217-233. (Pubitemid 43338093)
20. Werle M, Makhlof A, Takeuchi H. Oral protein delivery: a patent review of academic and industrial approaches. Recent Pat Drug Deliv Formul. 2009;3:94-104.
21. John MR, Haemmerle S, Launonen A, Harfst E, Azria M, Arnold M, Mindeholm L. A novel oral parathyroid hormone formulation, PTH134, demonstrated a potential therapeutically relevant pharmacokinetic and safety profile compared with teriparatide sc in healthy postmenopausal women after a single dose [abstract]. Arthritis and Rheumatism. 2009;887. http://acr.confex.com/acr/2009/ webprogram/Paper14353.html. Accessed May 25, 2010.
22. Steinert RE, Poller B, Castelli MC, et al. Orally administered glucagon-like peptide-1 affects glucose homeostasis following an oral glucose tolerance test in healthy male subjects. Clin Pharmacol Ther. 2009;86:644-650.
23. Chin CM, Gutierrez M, Still JG, Kosutic G. Pharmacokinetics of modified oral calcitonin product in healthy volunteers. Pharmacotherapy. 2004;24:994-1001. (Pubitemid 39025199)
24. Leone-Bay A, McInnes C, Wang N, et al. Microsphere formation in a series of derivatized alpha-amino acids: properties, molecular modeling, and oral delivery of salmon calcitonin. J Med Chem. 1995;38:4257-4262.
25. Cheng W, Lim LY. Synthesis, characterization and in vivo activity of salmon calcitonin coconjugated with lipid and polyethylene glycol. J Pharm Sci. 2009;98:1438-1451.
26. Cheng W, Lim LY. Lipeo-sCT: a novel reversible lipidized salmon calcitonin derivative, its biophysical properties and hypocalcemic activity. Eur J Pharm Sci. 2009;37:151-159.
27. Cheng W, Satyanarayanajois S, Lim LY. Aqueous-soluble, non-reversible lipid conjugate of salmon calcitonin: synthesis, characterization and in vivo activity. Pharm Res. 2007;24:99-110.
28. Woodley JF. Enzymatic barriers for GI peptide and protein delivery. Crit Rev Ther Drug Carrier Syst. 1994;11:61-95.
29. Bernkop-Schnurch A. The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins. J Control Release. 1998;52:1-16. (Pubitemid 28123168)
30. Mahato RI, Narang AS, Thoma L, Miller DD. Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst. 2003;20:153-214. (Pubitemid 37237279)
31. Kidron M, Dinh S, Menachem Y, et al. A novel per-oral insulin formulation: proof of concept study in non-diabetic subjects. Diabet Med. 2004;21:354-357. (Pubitemid 38519671)
32. Nissan A, Ziv E, Kidron M, et al. Intestinal absorption of low molecular weight heparin in animals and human subjects. Haemostasis. 2000;30:225-232. (Pubitemid 32225727)
33. Ziv E, Kidron M, Raz I, et al. Oral administration of insulin in solid form to nondiabetic and diabetic dogs. J Pharm Sci. 1994;83:792-794. (Pubitemid 24233751)
34. Bendayan M, Ziv E, Gingras D, Ben-Sasson R, Bar-On H, Kidron M. Biochemical and morpho-cytochemical evidence for the intestinal absorption of insulin in control and diabetic rats: comparison between the effectiveness of duodenal and colon mucosa. Diabetologia. 1994;37:119-126. (Pubitemid 24042878)
35. Kidron M, Bar-On H, Berry EM, Ziv E. The absorption of insulin from various regions of the rat intestine. Life Sci. 1982;31:2837-2841. (Pubitemid 13212452)
36. Damge C, Reis CP, Maincent P. Nanoparticle strategies for the oral delivery of insulin. Expert Opin Drug Deliv. 2008;5:45-68. (Pubitemid 351234109)
37. Damge C, Reis CP, Maincent P. Nanoparticle strategies for the oral delivery of insulin. Expert Opin Drug Deliv. 2008;5:45-68. (Pubitemid 351234109)
38. Wong TW. Chitosan and its use in design of insulin delivery system. Recent Pat Drug Deliv Formul. 2009;3:8-25.
39. Chalasani KB, Russell-Jones GJ, Jain AK, Diwan PV, Jain SK. Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles. J Control Release. 2007;122: 141-150. (Pubitemid 47361403)
40. Chalasani KB, Russell-Jones GJ, Yandrapu SK, Diwan PV, Jain SK. A novel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin. J Control Release. 2007;117:421-429. (Pubitemid 46237606)
41. Karsdal MA, Henriksen K, Leeming DJ, et al. Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers. 2009;14: 181-202.
42. Schaller S, Henriksen K, Hoegh-Andersen P, et al. In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist? Assay Drug Dev Technol. 2005;3:553-580.
43. Schaller S, Henriksen K, Sveigaard C, et al. The chloride channel inhibitor n53736 prevents bone resorption in ovariectomized rats without changing bone formation. J Bone Miner Res. 2004;19:1144-1153. (Pubitemid 41110567)
44. Ravn P, Hosking D, Thompson D, et al. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab. 1999;84:2363-2368.
45. Sondergaard BC, Henriksen K, Wulf H, et al. Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation. Osteoarthritis Cartilage. 2006;14:738-748. (Pubitemid 43986357)
46. Nielsen RH, Stoop R, Leeming DJ, Stolina M, Qvist P, Christiansen C, Karsdal MA. Evaluation of cartilage damage by measuring collagen degradation products in joint extracts in a traumatic model of osteoarthritis. Biomarkers. 2008;13:79-87.
47. Reijman M, Hazes JM, Bierma-Zeinstra SM, et al. A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum. 2004;50:2471-2478. (Pubitemid 39062707)
48. Dam EB, Byrjalsen I, Karsdal MA, Qvist P, Christiansen C. Increased urinary excretion of C-telopeptides of type II collagen (CTX-II) predicts cartilage loss over 21 months by MRI. Osteoarthritis Cartilage. 2009;17:384-389.
49. Dam EB, Loog M, Christiansen C, et al. Identification of progressors in osteoarthritis by combining biochemical and MRI-based markers. Arthritis Res Ther. 2009;11:R115.
50. Leone-Bay A, Santiago N, Achan D, et al. N-acylated alpha-amino acids as novel oral delivery agents for proteins. J Med Chem. 1995;38:4263-4269.
51. Malkov D, Angelo R, Wang HZ, Flanders E, Tang H, Gomez-Orellana I. Oral delivery of insulin with the eligen technology: mechanistic studies. Curr Drug Deliv. 2005;2:191-197. (Pubitemid 40488628)
52. Mlynek GM, Calvo LJ, Robinson JR. Carrier-enhanced human growth hormone absorption across isolated rabbit intestinal tissue. Int J Pharm. 2000;197:13-21. (Pubitemid 30125773)
53. Wu SJ, Robinson JR. Transcellular and lipophilic complex-enhanced intestinal absorption of human growth hormone. Pharm Res. 1999;16:1266-1272. (Pubitemid 29393617)
54. Copp DH, Cameron EC, Cheney BA, Davidson AG, Henze KG. Evidence for calcitonin - a new hormone from the parathyroid that lowers blood calcium. Endocrinology. 1962;70:638-49.
55. Kumar MA, Foster GV, MacIntyre I. Further evidence for calcitonin. a rapid-acting hormone which lowers plasma-calcium. Lancet. 1963;35:480-482.
56. Chambers TJ, Moore A. The sensitivity of isolated osteoclasts to morphological transformation by calcitonin. J Clin Endocrinol Metab. 1983;57:819-824
57. Suzuki H, Nakamura I, Takahashi N, et al. Calcitonin-induced changes in the cytoskeleton are mediated by a signal pathway associated with protein kinase A in osteoclasts. Endocrinology. 1996;137:4685-4690. (Pubitemid 26403306)
58. Shyu JF, Shih C, Tseng CY, et al. Calcitonin induces podosome disassembly and detachment of osteoclasts by modulating Pyk2 and Src activities. Bone. 2007;40:1329-1342. (Pubitemid 46550990)
59. Sorensen MG, Henriksen K, Schaller S, et al. Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral blood. J Bone Miner Metab. 2007;25:36-45. (Pubitemid 46012995)
60. Nicholson GC, Moseley JM, Sexton PM, Mendelsohn FA, Martin TJ. Abundant calcitonin receptors in isolated rat osteoclasts: biochemical and autoradiographic characterization. J Clin Invest1986;78:355-360.
61. Sexton PM, Findlay DM, Martin TJ. Calcitonin. Curr Med Chem. 1999;6:1067-1093.
62. Hilton JM, Dowton M, Houssami S, Sexton PM. Identification of key components in the irreversibility of salmon calcitonin binding to calcitonin receptors. J Endocrinol. 2000;166:213-226. (Pubitemid 30435891)
63. Purdue BW, Tilakaratne N, Sexton PM. Molecular pharmacology of the calcitonin receptor. Receptors Channels. 2002;8:243-255.
64. Deftos LJ, Lee MR, Potts JT Jr. A radioimmunoassay for thyrocalcitonin. Proc Natl Acad Sci U S A. 1968;60:293-9.
65. Karsdal MA, Henriksen K, Arnold M, Christiansen C. Calcitonin: a drug of the past or for the future? Physiologic inhibition of bone resorption while sustaining osteoclast numbers improves bone quality. BioDrugs. 2008;22:137-144. (Pubitemid 351692844)
66. Karsdal MA, Byrjalsen I, Azria M, et al. Influence of food intake on the bioavailability and efficacy of oral calcitonin. Br J Clin Pharmacol. 2009;67:413-420.
67. Karsdal MA, Byrjalsen I, Riis BJ, Christiansen C. Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of Salmon Calcitonin. BMC Clin Pharmacol. 2008;8:5.
68. Karsdal MA, Byrjalsen I, Riis BJ, Christiansen C. Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteoporosis with oral calcitonin. BMC Clin Pharmacol. 2008;8:12.
69. Karsdal MA, Byrjalsen I, Henriksen K, Riis BJ, Christiansen C. A pharmacokinetic and pharmacodynamic comparison of synthetic and recombinant oral salmon calcitonin. J Clin Pharmacol. 2009;49: 229-234.
70. Shimoyama Y, Kusano M, Kawamura O, et al. High-viscosity liquid meal accelerates gastric emptying. Neurogastroenterol Motil. 2007;19:879-886. (Pubitemid 350060609)
71. Karsdal MA, Byrjalsen I, Leeming DJ, Delmas PD, Christiansen C. The effects of oral calcitonin on bone collagen maturation: implications for bone turnover and quality. Osteoporos Int. 2008;19:1355-1361.
72. Jusko WJ, Ko HC. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther. 1994;56:406-419. (Pubitemid 24339087)
73. Karsdal MA, Byrjalsen I, Henriksen K, Riis BJ, Christiansen C. Investigations of inter- and intraindividual relationships between exposure to oral salmon calcitonin and a surrogate marker of pharmacodynamic efficacy. Eur J Clin Pharmacol. 2010;66:29-37.
74. Gertz BJ, Clemens JD, Holland SD, Yuan W, Greenspan S. Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment. Calcif Tissue Int. 1998;63:102-106. (Pubitemid 28347681)
75. Sostek MB, Chen Y, Andersson T. Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole. Br J Clin Pharmacol. 2007;64:386-390. (Pubitemid 47283859)
76. Lentz KA, Quitko M, Morgan DG, Grace JE Jr, Gleason C, Marathe PH. Development and validation of a preclinical food effect model. J Pharm Sci. 2007;96:459-472. (Pubitemid 46363575)
77. Karara AH, Dunning BE, McLeod JF. The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects. J Clin Pharmacol. 1999;39:172-179. (Pubitemid 29068163)
78. Schlemmer A, Hassager C, Jensen SB, Christiansen C. Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women. J Clin Endocrinol Metab. 1992;74:476-480.
79. Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone. 2002;31:57-61. (Pubitemid 34754426)
80. Karsdal MA, Byrjalsen I, Henriksen K, et al. The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study. Osteoarthritis Cartilage. 2010;18:150-159.